Citadel Advisors’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Citadel Advisors’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-48,400	Closed	-$1.33M	–	15256
2021 Q2	$1.33M	Sell	48,400 -7,600	-14%	-$149K	﹤0.01%	7598
2021 Q1	$923K	Buy	56,000 +33,400	+148%	+$761K	﹤0.01%	8323
2020 Q4	$417K	Buy	22,600 +8,500	+60%	+$152K	﹤0.01%	8477
2020 Q3	$192K	Sell	14,100 -9,900	-41%	-$153K	﹤0.01%	8843
2020 Q2	$430K	Buy	24,000 +4,100	+21%	+$61.8K	﹤0.01%	7333
2020 Q1	$198K	Buy	+19,900	New	+$163K	﹤0.01%	8024

Citadel Advisors's TBIO Position: Q2 2021 in Review

Citadel Advisors sold out of Translate Bio, Inc. Common Stock (TBIO) in Q2 2021, closing a stake of 23,287 shares — an estimated $458K sold.

Citadel Advisors first reported a position in TBIO in Q1 2020 and held it in 5 quarters. The position peaked at $6.56M in Q2 2020. 145 funds tracked by Wall St. Rank hold TBIO as of Q2 2021.

Citadel Advisors reported no remaining Translate Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Citadel Advisors sold 23,287 Translate Bio, Inc. Common Stock shares in Q2 2021, an estimated $458K.
Citadel Advisors first reported a position in Translate Bio, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
Citadel Advisors's Translate Bio, Inc. Common Stock position peaked at $6.56M in Q2 2020.
145 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q2 2021.

Based on Citadel Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.